Safety and Effectiveness of Giving Adefovir Dipivoxil Plus Abacavir Plus Efavirenz Plus Amprenavir to HIV-Infected Patients Who Have Failed to Respond to Previous Protease Inhibitor Treatment - Contacts and Locations

Safety and Effectiveness of Giving Adefovir Dipivoxil Plus Abacavir Plus Efavirenz Plus Amprenavir to HIV-Infected Patients Who Have Failed to Respond to Previous Protease Inhibitor Treatment

This study has been completed.

Study NCT00002419. Last updated on June 23, 2005. Information provided by NIH AIDS Clinical Trials Information Service

Please refer to this study by its ClinicalTrials.gov identifier: NCT00002419

Locations


United States, California
	Pacific Oaks Med Group
	Beverly Hills, California, United States, 90211

United States, Colorado
	Univ of Colorado / Health Science Ctr
	Denver, Colorado, United States, 80262

United States, Georgia
	AIDS Research Consortium of Atlanta
	Atlanta, Georgia, United States, 30308

United States, Rhode Island
	Brown Univ School of Medicine
	Providence, Rhode Island, United States, 02908

United States, Virginia
	Hampton Roads Med Specialists
	Hampton, Virginia, United States, 23666

Sponsors and Collaborators

Gilead Sciences

Glaxo Wellcome

Dupont Pharmaceuticals